Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00332631
Registration number
NCT00332631
Ethics application status
Date submitted
31/05/2006
Date registered
1/06/2006
Date last updated
7/07/2009
Titles & IDs
Public title
High-Dose N-Acetylcysteine in Cardiac Surgery
Query!
Scientific title
High-Dose N-Acetylcysteine in Cardiac Surgery Patients at High-Risk of Postoperative Renal Dysfunction.
Query!
Secondary ID [1]
0
0
H2004/01899
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cardiac Surgery and Cardiopulmonary Bypass
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Absolute change in serum creatinine from baseline to peak level within the first five postoperative days.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [1]
0
0
Relative change in serum creatinine,
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Query!
Secondary outcome [2]
0
0
Highest serum creatinine,
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Query!
Secondary outcome [3]
0
0
Change in estimated glomerular filtration rate (eGFR),
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Query!
Secondary outcome [4]
0
0
Change in serum cystatin C (as a serum creatinine-independent marker of renal function during and after NAC administration (Hoffmann et al. JASN 2004),
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Query!
Secondary outcome [5]
0
0
Urinary output
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Query!
Secondary outcome [6]
0
0
Use of renal replacement therapy (RRT)
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Query!
Secondary outcome [7]
0
0
Acute renal dysfunction
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Query!
Secondary outcome [8]
0
0
Duration of ventilation,
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Query!
Secondary outcome [9]
0
0
Chest tube drainage,
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Query!
Secondary outcome [10]
0
0
Need for return to operating room,
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Query!
Secondary outcome [11]
0
0
Incidence of post-operative atrial fibrillation (AF),
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
Query!
Secondary outcome [12]
0
0
Duration of stay in the intensive care unit (ICU)
Query!
Assessment method [12]
0
0
Query!
Timepoint [12]
0
0
Query!
Secondary outcome [13]
0
0
Duration of stay in hospital
Query!
Assessment method [13]
0
0
Query!
Timepoint [13]
0
0
Query!
Eligibility
Key inclusion criteria
* Age above 70 years
* Preexisting renal impairment (preoperative serum creatinine level >120µmol/L
* New York Heart Association class III/IV or Moderate to poor left ventricular dysfunction
* Valve surgery or complex cardiac surgery
* Redo cardiac surgery
* Insulin-dependent diabetes mellitus
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Age <18 years
* Known allergy or hypersensitivity to N-acetylcysteine
* Emergency cardiac surgery
* Planned off-pump cardiac surgery
* Enrolled in conflicting research study
* Known blood-borne infectious disease
* Chronic inflammatory disease on immunosuppression
* Chronic moderate to high dose corticosteroid therapy (>10mg/d prednisone or equivalent)
* End stage renal disease (serum creatinine >300µmol/L)
* Patients receiving pre-op IV nitrates
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Austin Hospital - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
3084 - Melbourne
Query!
Funding & Sponsors
Primary sponsor type
Government body
Query!
Name
Austin Health
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
At least 14% of patients develop kidney failure after cardiac surgery. Although this kidney failure can usually be treated effectively, a longer stay in intensive care is often required. While many patients suffer no long term ill effects after developing post-operative kidney failure, some require long term kidney dialysis. The investigators also know that patients who develop post-operative kidney failure are much more likely to die before they leave hospital. Why some people develop kidney failure after cardiac surgery is not known. However, doctors suspect that the process of cardiopulmonary bypass (where the functions of the heart and lungs are taken over by a machine during the operation, to allow the surgeon to operate) overactivates some of the same mechanisms the body uses to defend itself against severe infection. Many of the cell changes by which severe infection causes kidney failure also occur after cardiopulmonary bypass. One of the main overactive defence mechanisms is the release of highly toxic compounds derived from oxygen - a process called 'oxidative stress'. Another well-known cause of oxidative stress is paracetamol (Panadol) overdose. In large doses the oxidative stress caused by paracetamol damages cells in the liver, where it is digested, and the kidney. N-acetylcysteine is a drug in common use for the treatment of paracetamol overdose. Patients who would otherwise die of liver failure are routinely saved by N-acetylcysteine, which acts as a strong anti-oxidant. The investigators believe that N-acetylcysteine might similarly reduce the oxidative stress which occurs during cardiac surgery, and so prevent or decrease the kidney failure which occurs in many patients. The investigators hope to give N-acetylcysteine (in similar doses to those used safely for paracetamol poisoning) to patients during, and for a day after cardiac surgery, and compare the effects with patients who have not had N-acetylcysteine. The drug, or a 5% glucose placebo, will be given through the drip which is present in all cardiac surgery patients. Whether a particular patient receives the drug or placebo will be decided at random, and neither the patient nor the investigators will know which has been given. The investigators will measure kidney function before and after the operation using the standard tests which are performed for the purposes of clinical care of every patient. Also, the investigators will do an extra test involving the collection of urine (from the urinary catheter every patient has after cardiac surgery), which provides an even better measure of kidney function. This is a potential benefit to the patient, as while this test is not routinely performed, the results will be available to the doctors in the intensive care unit. The investigators will also take four 20ml samples of blood, spaced before, during, and after the operation, from the arterial catheter routinely inserted in every patient. This is an insignificant amount of blood compared to that taken for other tests, and would have no adverse effects. This blood would be used to measure oxidative stress, and also some of the proteins inside the blood cells which are responsible for creating the toxic oxygen compounds. In this way the investigators will discover not only the effect of N-acetylcysteine, but the mechanism of that effect. N-acetylcysteine is routinely used to treat paracetamol overdose with few side effects. An itchy skin rash is the only common side effect. Sometimes patients develop nausea and vomiting, but the treatment for this is usually very effective, and the drug will be stopped if it occurs. Rarely, as with all drugs, allergic reactions have been reported, but there are no other reported adverse effects. There will be no extra risk to a patient who participates in the study, and no discomfort other than that normally associated with cardiac surgery. The itchy rash which occasionally develops with N-acetylcysteine would occur under anaesthetic, and would almost certainly be gone by the time the patient wakes up. Informed consent will be obtained from the patient prior to the operation by one of the investigators or the ICU research nurse.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00332631
Query!
Trial related presentations / publications
Haase M, Haase-Fielitz A, Ratnaike S, Reade MC, Bagshaw SM, Morgera S, Dragun D, Bellomo R. N-Acetylcysteine does not artifactually lower plasma creatinine concentration. Nephrol Dial Transplant. 2008 May;23(5):1581-7. doi: 10.1093/ndt/gfm818. Epub 2008 Jan 17.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Rinaldo Bellomo, MD, FRACP
Query!
Address
0
0
Austin Health
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT00332631
Download to PDF